These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 24532028)

  • 1. Transdermal therapy for attention-deficit hyperactivity disorder with the methylphenidate patch (MTS).
    Findling RL; Dinh S
    CNS Drugs; 2014 Mar; 28(3):217-28. PubMed ID: 24532028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methylphenidate transdermal system: In attention-deficit hyperactivity disorder in children.
    Anderson VR; Scott LJ
    Drugs; 2006; 66(8):1117-26. PubMed ID: 16789796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practical management of cutaneous reactions to the methylphenidate transdermal system: recommendations from a dermatology expert panel consensus meeting.
    Warshaw EM; Paller AS; Fowler JF; Zirwas MJ
    Clin Ther; 2008 Feb; 30(2):326-37. PubMed ID: 18343271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder.
    Findling RL; Bukstein OG; Melmed RD; López FA; Sallee FR; Arnold LE; Pratt RD
    J Clin Psychiatry; 2008 Jan; 69(1):149-59. PubMed ID: 18312050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of stimulants to treat ADHD: transdermal methylphenidate.
    Patrick KS; Straughn AB; Perkins JS; González MA
    Hum Psychopharmacol; 2009 Jan; 24(1):1-17. PubMed ID: 19051222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Critical assessment of the methylphenidate transdermal system.
    Kowalik S; Minami H; Silva RR
    Drugs Today (Barc); 2007 Aug; 43(8):515-27. PubMed ID: 17925883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials.
    Findling RL; Wigal SB; Bukstein OG; Boellner SW; Abikoff HB; Turnbow JM; Civil R
    Clin Ther; 2009 Aug; 31(8):1844-55. PubMed ID: 19808143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transdermal methylphenidate system: old wine in a new bottle.
    Bukstein OG
    Expert Opin Drug Metab Toxicol; 2009 Jun; 5(6):661-5. PubMed ID: 19442029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HRQL and medication satisfaction in children with ADHD treated with the methylphenidate transdermal system.
    Manos M; Frazier TW; Landgraf JM; Weiss M; Hodgkins P
    Curr Med Res Opin; 2009 Dec; 25(12):3001-10. PubMed ID: 19849639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD.
    McGough JJ; Wigal SB; Abikoff H; Turnbow JM; Posner K; Moon E
    J Atten Disord; 2006 Feb; 9(3):476-85. PubMed ID: 16481664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).
    Swanson JM; Wigal SB; Wigal T; Sonuga-Barke E; Greenhill LL; Biederman J; Kollins S; Nguyen AS; DeCory HH; Hirshe Dirksen SJ; Hatch SJ;
    Pediatrics; 2004 Mar; 113(3 Pt 1):e206-16. PubMed ID: 14993578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylphenidate transdermal system: in attention-deficit hyperactivity disorder in adolescents.
    Keating GM
    CNS Drugs; 2011 Apr; 25(4):333-42. PubMed ID: 21425884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of application to two different skin sites on the pharmacokinetics of transdermal methylphenidate in pediatric patients with attention-deficit/hyperactivity disorder.
    González MA; Campbell D; Rubin J
    J Child Adolesc Psychopharmacol; 2009 Jun; 19(3):227-32. PubMed ID: 19519257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching from oral extended-release methylphenidate to the methylphenidate transdermal system: continued attention-deficit/hyperactivity disorder symptom control and tolerability after abrupt conversion.
    Arnold LE; Bozzolo DR; Hodgkins P; McKay M; Beckett-Thurman L; Greenbaum M; Bukstein O; Patel A
    Curr Med Res Opin; 2010 Jan; 26(1):129-37. PubMed ID: 19916704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/hyperactivity disorder.
    Wilens TE; Boellner SW; López FA; Turnbow JM; Wigal SB; Childress AC; Abikoff HB; Manos MJ
    J Am Acad Child Adolesc Psychiatry; 2008 Jun; 47(6):700-708. PubMed ID: 18434918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 6-month, open-label, extension study of the tolerability and effectiveness of the methylphenidate transdermal system in adolescents diagnosed with attention-deficit/hyperactivity disorder.
    Findling RL; Katic A; Rubin R; Moon E; Civil R; Li Y
    J Child Adolesc Psychopharmacol; 2010 Oct; 20(5):365-75. PubMed ID: 20973707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.
    May DE; Kratochvil CJ
    Drugs; 2010; 70(1):15-40. PubMed ID: 20030423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methylphenidate transdermal system: clinical applications for attention-deficit/hyperactivity disorder.
    Elia J; Wilson Z; La Porta LS; Algon SA; Prowler ML; Cartwright ST; McKenna PA; Laracy S; Takeda T; Borgmann-Winter K
    Expert Rev Clin Pharmacol; 2011 May; 4(3):311-28. PubMed ID: 22114778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of methylphenidate transdermal system (MTS): results from a laboratory classroom study.
    Pierce D; Dixon CM; Wigal SB; McGough JJ
    J Child Adolesc Psychopharmacol; 2008 Aug; 18(4):355-64. PubMed ID: 18759645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder.
    Wilens TE; McBurnett K; Bukstein O; McGough J; Greenhill L; Lerner M; Stein MA; Conners CK; Duby J; Newcorn J; Bailey CE; Kratochvil CJ; Coury D; Casat C; Denisco MJ; Halstead P; Bloom L; Zimmerman BA; Gu J; Cooper KM; Lynch JM
    Arch Pediatr Adolesc Med; 2006 Jan; 160(1):82-90. PubMed ID: 16389216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.